| 1 |
NCT03229512 |
Recruiting |
Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction |
|
|
Interventional
|
Early Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Evidence of hand-foot skin reaction
- Adverse events due to 1% sildenafil cream
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03229512 |
JNC052716 |
|
April 11, 2017 |
December 2018 |
December 2018 |
July 25, 2017 |
November 13, 2017 |
|
- Department of Dermatology, Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States - Northwestern Memorial Hospital
Chicago, Illinois, United States
|
|
| 2 |
NCT03598140 |
Recruiting |
Sildenafil Treatment for Mild TBI |
- Vascular System Injuries
- Concussion, Brain
- Post-Concussion Syndrome
|
- Drug: Sildenafil Citrate
- Drug: Placebo oral capsule
|
Interventional
|
Phase 2 |
- University of Texas Southwestern Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Arterial Spin Labeling
- Rivermead Post Concussion Symptoms Questionnaire (RPQ)
- Hopkins Verbal Learning Task (HVLT)
- BOLD MRI with hypercapnia
|
180 |
Male |
18 Years to 35 Years (Adult) |
NCT03598140 |
032018-063 |
|
July 25, 2018 |
June 30, 2021 |
December 31, 2021 |
July 25, 2018 |
August 28, 2018 |
|
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
|
|
| 3 |
NCT02466802 |
Recruiting |
Study of Regorafenib and Sildenafil for Advanced Solid Tumors |
|
- Drug: Regorafenib
- Drug: Sildenafil Citrate
|
Interventional
|
Phase 1 |
- Virginia Commonwealth University
- Bayer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the recommended phase 2 dose (RP2D) of the combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.
- To evaluate the safety and toxicity of the regorafenib and sildenafil combination
- To explore the antitumor effects of the regorafenib and sildenafil combination
- (and 2 more...)
|
37 |
All |
18 Years and older (Adult, Older Adult) |
NCT02466802 |
MCC-13-09812
HM20004297
NCI-2015-01101 |
|
July 1, 2015 |
August 31, 2018 |
June 30, 2019 |
June 9, 2015 |
January 26, 2018 |
|
- Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, United States
|
|
| 4 |
NCT02812433 |
Recruiting |
Sildenafil Administration to Treat Neonatal Encephalopathy |
|
- Drug: Sildenafil
- Drug: Ora-Blend
|
Interventional
|
Phase 1 |
- McGill University Health Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Serious adverse events
- Plasmatic concentrations of sildenafil and N-desmethyl sildenafil
|
80 |
All |
up to 48 Hours (Child) |
NCT02812433 |
15-364-MUHC |
SANE |
July 2016 |
June 2022 |
June 2022 |
June 24, 2016 |
August 30, 2017 |
|
- Montreal Children's Hospital
Montreal, Quebec, Canada
|
|
| 5 |
NCT02908490 |
Recruiting |
Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis? |
- Arthritis, Rheumatoid
- Atherosclerosis
|
- Drug: Sildenafil
- Other: Placebo
|
Interventional
|
Phase 2 |
- Kimberly Liang
- University of Pittsburgh
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Brachial Artery Flow Mediated Dilation (FMD) Without Nitroglycerin
- Peripheral Arterial Tone (PAT)
- Biomarkers for inflammation-1
- (and 13 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02908490 |
PRO14120209 |
|
April 1, 2017 |
July 2019 |
December 2019 |
September 21, 2016 |
February 13, 2018 |
|
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
|
| 6 |
NCT03177824 |
Recruiting |
Sildenafil Citrate for Treatment of Growth-restricted Fetuses |
|
- Drug: Sildenafil Citrate 25Mg Tab
- Drug: Placebo Oral Tablet
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- date of delivery after Sildenafil citrate administration.
- Expected fetal weight by serial ultrasound after Sildenafil citrate administration
- Color Doppler changes on umbilical artery
- (and 2 more...)
|
60 |
Female |
20 Years to 40 Years (Adult) |
NCT03177824 |
123sc |
|
March 30, 2017 |
September 30, 2017 |
October 1, 2017 |
June 6, 2017 |
June 9, 2017 |
|
- Ain Shams matrnity hospital
Cairo, Egypt
|
|
| 7 |
NCT03028298 |
Recruiting |
Sildenafil for DCI |
- Subarachnoid Hemorrhage
- Cerebral Vasospasm
|
- Drug: Low dose sildenafil citrate
- Drug: High dose sildenafil citrate
|
Interventional
|
Phase 1 |
- University of Mississippi Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline in mean arterial blood pressure
- Area under the plasma concentration versus time curve (AUC) of sildenafil
- Area under the cerebral spinal fluid concentration versus time curve (AUC) of sildenafil
- Change from baseline in cerebral autoregulation
|
24 |
All |
21 Years and older (Adult, Older Adult) |
NCT03028298 |
2016-0134 |
|
December 2016 |
December 2018 |
July 2019 |
January 23, 2017 |
February 14, 2018 |
|
- University of Mississippi Medical Center
Jackson, Mississippi, United States
|
|
| 8 |
NCT03356353 |
Recruiting |
Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation |
|
|
Interventional
|
Phase 3 |
- University of Calgary
- Pfizer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Pulmonary vascular resistance (PVR)
- Right heart failure (RHF)
- RHF
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT03356353 |
RVD102017 |
|
March 12, 2018 |
June 2019 |
September 2019 |
November 29, 2017 |
May 3, 2018 |
|
- University of Calgary
Calgary, Alberta, Canada - University of Calgary
Calgary, Alberta, Canada
|
|
| 9 |
NCT03417492 |
Recruiting |
Cerebrovascular Reactivity in American Football Players |
- Traumatic Brain Injury
- Mild Traumatic Brain Injury
- Post-Concussion Syndrome
|
|
Interventional
|
Phase 1 |
- University of Pennsylvania
- Boston University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Effect of single dose sildenafil citrate treatment on global blood oxygen level-dependent (BOLD) response to hypercapnia.
- Effect of single dose sildenafil citrate treatment on functional near-infrared spectroscopy (fNIRS) response to hypercapnia.
- Maximum tolerable dose of sildenafil therapy without severe adverse events.
|
30 |
Male |
40 Years to 65 Years (Adult, Older Adult) |
NCT03417492 |
827103 |
|
March 1, 2018 |
September 1, 2019 |
September 1, 2019 |
January 31, 2018 |
April 12, 2018 |
|
- Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
|
|
| 10 |
NCT03154476 |
Recruiting |
Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study |
- Cirrhosis
- Congenital Heart Disease
|
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Change in liver stiffness as measured by magnetic resonance elastography (MRE)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03154476 |
16-008985 |
SiFALD |
July 5, 2017 |
June 2019 |
June 2019 |
May 16, 2017 |
September 11, 2017 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
|
| 11 |
NCT03262961 |
Recruiting |
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia |
|
- Drug: Sildenafil 20 MG
- Drug: Placebo Oral Tablet
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Gestational age at time of termination and maternal outcome.
- Neonatal outcome.
- Control of maternal blood pressure.
- (and 3 more...)
|
80 |
Female |
18 Years to 35 Years (Adult) |
NCT03262961 |
assiutu252 |
|
September 15, 2016 |
December 15, 2017 |
January 15, 2018 |
August 28, 2017 |
August 28, 2017 |
|
- Assiut Univeristy Hospitals
Assiut, Egypt
|
|
| 12 |
NCT03142568 |
Recruiting |
Safety of Sildenafil in Premature Infants |
- Bronchopulmonary Dysplasia
|
- Drug: Sildenafil
- Other: Placebo
|
Interventional
|
Phase 2 |
- University of North Carolina, Chapel Hill
- Duke University
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- The EMMES Corporation
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety as determined by adverse event experienced by participants
- Volume of Distribution
- Clearance
- (and 4 more...)
|
120 |
All |
up to 28 Days (Child) |
NCT03142568 |
17-2436
HHSN27500039 |
SIL02 |
April 2, 2018 |
June 2019 |
August 2019 |
May 5, 2017 |
August 13, 2018 |
|
- Riley Hospital for Children at IU Health
Indianapolis, Indiana, United States - Wesley Medical Center
Wichita, Kansas, United States - Ochsner Baptist Medical Center
New Orleans, Louisiana, United States - (and 6 more...)
|
|
| 13 |
NCT03402191 |
Recruiting |
L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension |
|
- Drug: L-arginine
- Drug: Sildenafil
|
Interventional
|
Phase 4 |
- Sherief Abd-Elsalam
- Tanta University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with improvement of pulmonary hypertension
|
60 |
All |
6 Years to 18 Years (Child, Adult) |
NCT03402191 |
Prof Elshanshoury |
|
July 2016 |
December 2023 |
December 2023 |
January 18, 2018 |
August 27, 2018 |
|
- Sherief Abd-Elsalam
Tanta, Egypt
|
|
| 14 |
NCT03460470 |
Recruiting |
Sildenafil in US Heart Failure Patients (SilHF-US) |
- Heart Failure
- Pulmonary Hypertension
|
- Drug: Sildenafil
- Drug: Placebo oral capsule
|
Interventional
|
Phase 3 |
- Hartford Hospital
- Helse Stavanger HF
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Six minute walk test
- Patient Global Assessment (PGA)
- 1.Quality of Life (QoL) evaluation by EuroQol5D
- (and 2 more...)
|
25 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03460470 |
HHC-2016-0152 |
SilHF-US |
February 14, 2018 |
December 2018 |
December 2018 |
March 9, 2018 |
March 9, 2018 |
|
- Hartford Hospital 80 Seymour street
Hartford, Connecticut, United States
|
|
| 15 |
NCT01616381 |
Active, not recruiting |
Sildenafil Versus Placebo in Chronic Heart Failure |
- Heart Failure
- Pulmonary Hypertension
|
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Patient Global Assessment
- Six minute walk test
- Quality of Life (QoL) evaluation by EuroQol5D
- (and 2 more...)
|
75 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01616381 |
SUS2011DIKE01
2011-002829-21 |
SilHF |
March 2013 |
June 2018 |
December 2019 |
June 11, 2012 |
May 7, 2018 |
|
- Lady Davis Carmel Medical CEnter
Haifa, Israel - Rabin Medical Center
Petah Tikva, Israel - San Donato Hospital
Milano, Italy - (and 3 more...)
|
|
| 16 |
NCT03192709 |
Recruiting |
Sildenafil and Outcome of IVF/ICSI Cycles |
|
- Drug: Sildenafil vaginal suppositories
- Other: vaginal placebo
|
Interventional
|
Phase 1
Phase 2 |
- Royan Institute
- Tehran University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical Pregnancy rate
- Implantation rate
- Endometrial thickness
- (and 3 more...)
|
60 |
Female |
16 Years to 38 Years (Child, Adult) |
NCT03192709 |
Royan-Emb-030 |
|
February 2015 |
August 2017 |
September 2017 |
June 20, 2017 |
June 20, 2017 |
|
- Royan Institute
Tehrān, Iran, Islamic Republic of
|
|
| 17 |
NCT02435303 |
Active, not recruiting |
Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial) |
- Hypertension, Pulmonary
- Diseases of Mitral Valve
|
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change of Six Minutes Walk Distance
- Borg dyspnea score
- Exercise capacity by cardiopulmonary exercise test
- (and 4 more...)
|
46 |
All |
Child, Adult, Older Adult |
NCT02435303 |
MVsurgery_PAH |
SUPERIOR |
May 2016 |
December 2018 |
December 2019 |
May 6, 2015 |
January 10, 2018 |
|
|
|
| 18 |
NCT02930811 |
Not yet recruiting |
Efficacy of Sildenafil on the Morbi-mortality of Peripheral Arterial Diseased Patients With Intermittent Claudication |
- Peripheral Arterial Occlusive Disease
|
- Drug: Sildenafil 100 mg oral morning dose
- Drug: Placebo oral morning dose
|
Interventional
|
Phase 3 |
- University Hospital, Angers
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Improvement of Event free survival rate
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT02930811 |
PHRC-N-2015 |
VALSTAR |
June 2017 |
March 2019 |
March 2019 |
October 12, 2016 |
April 14, 2017 |
|
|
|
| 19 |
NCT03169582 |
Recruiting |
Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction |
|
- Drug: Avanafil
- Drug: Sildenafil
|
Interventional
|
Phase 4 |
- Eduardo Vargas-Baquero
- Hospital Nacional de Parapléjicos de Toledo
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
78 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03169582 |
HNParaplejicos |
|
April 1, 2016 |
June 1, 2018 |
June 1, 2018 |
May 30, 2017 |
May 30, 2017 |
|
- Hospital Nacional de Paraplejicos
Toledo, Spain
|
|
| 20 |
NCT02983461 |
Recruiting |
Use of Sildenafil for Treatment of Urinary Incontinence |
|
- Drug: Sildenafil
- Drug: Placebo Oral Tablet
|
Interventional
|
Phase 1 |
- The University of Texas Medical Branch, Galveston
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Urinary Incontinence as measured by Pad Test
|
24 |
Female |
50 Years to 80 Years (Adult, Older Adult) |
NCT02983461 |
15-0121 |
|
March 10, 2017 |
March 2019 |
March 2019 |
December 6, 2016 |
July 11, 2018 |
|
- University of Texas Medical Branch
Galveston, Texas, United States
|
|
| 21 |
NCT02519153 |
Active, not recruiting |
Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) as Medical Expulsive Therapy in Distal Ureteral Stones |
- Ureteral Stone
- Urolithiasis
|
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- the percentage of passage of lower ureteric stones.
- number of patient need for analgesic treatment during their medical expulsive tharpy
|
100 |
Male |
18 Years to 70 Years (Adult, Older Adult) |
NCT02519153 |
MThar87 |
|
July 2014 |
August 2017 |
September 2017 |
August 10, 2015 |
July 5, 2017 |
|
|
|
| 22 |
NCT02335242 |
Recruiting |
Sildenafil for the Treatment of Lymphatic Malformations |
- Lymphatic Malformations
- Lymphatic Diseases
|
- Drug: Sildenafil 20 mg tablets
- Other: Placebo tablets (resembling Revatio)
|
Interventional
|
Phase 2 |
- Stanford University
- Ann & Robert H Lurie Children's Hospital of Chicago
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Change in lesion volume of the test medication as evaluated by MRI examination.
- Change in lesion volume estimated using a soft tape measure to measure the length, width, and hemispheric measurement of each of the lymphatic malformations.
- Subject's evaluation of the change in lesion clinical characteristics.
|
40 |
All |
6 Months to 10 Years (Child) |
NCT02335242 |
23400
R01FD004372 |
|
May 23, 2015 |
April 2021 |
December 2022 |
January 9, 2015 |
March 15, 2018 |
|
- Stanford University
Stanford, California, United States - University of Colorado, Denver
Aurora, Colorado, United States - Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
|
|
| 23 |
NCT03230162 |
Recruiting |
Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment |
- Fetal Growth Abnormality
- Fetal Growth Restriction
|
- Drug: Sildenafil
- Drug: low molecular weight heparin
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Neonatal birth weight in grams
- The change in Doppler velocity indices,
- Fetal growth velocity
- (and 5 more...)
|
100 |
Female |
20 Years to 35 Years (Adult) |
NCT03230162 |
Ain shams university maternity |
|
June 1, 2017 |
May 1, 2018 |
May 1, 2018 |
July 26, 2017 |
July 26, 2017 |
|
- AinShams university maternity hospital
Cairo, Egypt
|
|
| 24 |
NCT01720524 |
Recruiting |
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn |
- Pulmonary Hypertension, Familial Persistent, of the Newborn
|
- Drug: placebo
- Drug: iv sildenafil
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time on inhaled nitric oxide treatment after initiation of iv study drug
- Treatment failure rate, defined as need for additional treatment targeting persistent pulmonary hypertension of the newborn.
- Time to final weaning of mechanical ventilation for persistent pulmonary hypertension of the newborn
- (and 4 more...)
|
64 |
All |
up to 4 Days (Child) |
NCT01720524 |
A1481316
2012-002619-24 |
|
August 5, 2013 |
December 31, 2018 |
December 31, 2020 |
November 2, 2012 |
September 3, 2018 |
|
- Arkansas Children's Hospital
Little Rock, Arkansas, United States - University of California Davis Medical Center
Sacramento, California, United States - University of California Davis
Sacramento, California, United States - (and 52 more...)
|
|
| 25 |
NCT02060487 |
Recruiting |
Effects of Oral Sildenafil on Mortality in Adults With PAH |
- Pulmonary Arterial Hypertension
|
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Time to first clinical worsening (TTCW) event
- 6 Minute Walk Distance (6MWD) at Months 6 & 12
|
429 |
All |
18 Years to 74 Years (Adult, Older Adult) |
NCT02060487 |
A1481324
2013-004362-34
AFFILIATE |
AFFILIATE |
September 22, 2014 |
December 31, 2023 |
December 31, 2023 |
February 12, 2014 |
July 20, 2018 |
|
- Emory University Investigational Drug Services
Atlanta, Georgia, United States - The Emory Clinic
Atlanta, Georgia, United States - Frederik Meijer Heart & Vascular Institute Cardiovascular Research
Grand Rapids, Michigan, United States - (and 75 more...)
|
|
| 26 |
NCT02951429 |
Recruiting |
Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension |
- Idiopathic Pulmonary Fibrosis
|
- Drug: Pirfenidone
- Drug: Placebo
- Drug: Sildenafil
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (>=) 15 Percent (%) From Baseline, Respiratory-Related Non-Elective Hospitalization, or Death From Any Cause
- Progression-Free Survival (PFS), Defined as Time to Decline in 6MWD of >=15% From Baseline, Respiratory-Related Non-Elective Hospitalization, or Death From Any Cause
- Percentage of Participants With Decline From Baseline in 6MWD of >= 15%
- (and 18 more...)
|
176 |
All |
40 Years to 80 Years (Adult, Older Adult) |
NCT02951429 |
MA29957
2015-005131-40 |
|
January 13, 2017 |
April 1, 2019 |
August 29, 2020 |
November 1, 2016 |
August 22, 2018 |
|
- ULB Hôpital Erasme
Brussels, Belgium - Cliniques Universitaires St-Luc
Bruxelles, Belgium - UZ Antwerpen
Edegem, Belgium - (and 56 more...)
|
|
| 27 |
NCT03364244 |
Recruiting |
Revavtio Special Investigation for Long-term Use in Pediatric Patients |
- Pulmonary Arterial Hypertension
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Incidence of adverse drug reactions
- Effictiveness rate for physician's evaluation of this product
- the dosage and administration under the actual use (including patients under the age of 1 year, weighing below 8 kg)
|
190 |
All |
up to 14 Years (Child) |
NCT03364244 |
A1481319 |
|
November 30, 2017 |
March 28, 2022 |
March 28, 2022 |
December 6, 2017 |
February 8, 2018 |
|
- Pfizer Local Country Office
Tokyo, Japan
|
|
| 28 |
NCT01817751 |
Recruiting |
Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma |
- Glioblastoma
- Recurrent Adult Brain Neoplasm
- Malignant Glioma
- WHO Grade III Glioma
|
- Drug: sorafenib tosylate
- Drug: valproic acid
- Drug: sildenafil citrate
|
Interventional
|
Phase 2 |
- Virginia Commonwealth University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS
- Overall best response rate (complete response + partial response) using RANO or Macdonald criteria.
- Overall survival
- Incidence of adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0
|
66 |
All |
18 Years and older (Adult, Older Adult) |
NCT01817751 |
MCC-14816
HM14816
NCI-2013-00705
P30CA016059 |
|
April 11, 2013 |
December 31, 2018 |
March 31, 2019 |
March 25, 2013 |
March 21, 2018 |
|
- Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, United States
|
|
| 29 |
NCT03185364 |
Recruiting |
The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD |
- COPD
- Pulmonary Hypertension
|
- Drug: Sildenafil Citrate
- Drug: Placebo Oral Tablet
|
Interventional
|
Not Applicable |
- Chinese Academy of Medical Sciences, Fuwai Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- pulmonary artery pressure
- pulmonary vascular resistance
|
46 |
All |
40 Years to 85 Years (Adult, Older Adult) |
NCT03185364 |
2016YFC1304401B |
|
June 15, 2017 |
December 31, 2020 |
December 31, 2020 |
June 14, 2017 |
June 14, 2017 |
|
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
|
|
| 30 |
NCT03044561 |
Recruiting |
Sildenafil Citrate of in Vitro Fertilization After Multiple IVF Failures Attributed to Poor Endometrial Development |
|
- Drug: Sildenafil Citrate
- Drug: matching placebo
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- endometrial thickness measures
|
80 |
Female |
20 Years to 40 Years (Adult) |
NCT03044561 |
amr el-sayed 2017 |
|
January 31, 2017 |
August 1, 2017 |
August 10, 2017 |
February 7, 2017 |
February 7, 2017 |
|
- Ain shams university
Cairo, Egypt
|
|
| 31 |
NCT02795351 |
Recruiting |
Induction of Migraine Aura With Sildenafil |
|
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Aura and migraine like headache
- Markers of endothelial function in blood
- Migraine without aura
|
16 |
All |
18 Years to 50 Years (Adult) |
NCT02795351 |
H-15008491 |
|
June 2015 |
June 2018 |
August 2018 |
June 10, 2016 |
March 22, 2018 |
|
- Department of Neurology, Herlev-Gentofte Hospital
Herlev, Denmark
|
|
| 32 |
NCT03199612 |
Not yet recruiting |
Hemolysis With Continuous Flow Pumps |
|
- Drug: Sildenafil
- Drug: Placebo Oral Tablet
|
Interventional
|
Early Phase 1 |
- Montefiore Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in platelet activation and aggregation (aggregometry)
- Change in P-Selectin levels
- Change in CD 40 ligand (L) levels
- (and 2 more...)
|
44 |
All |
18 Years and older (Adult, Older Adult) |
NCT03199612 |
2016-7404 |
|
December 1, 2018 |
June 30, 2022 |
August 30, 2022 |
June 27, 2017 |
March 23, 2018 |
|
|
|
| 33 |
NCT02682147 |
Recruiting |
Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema |
|
|
Interventional
|
Phase 4 |
- Eric A. Hoffman
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Iowa
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Dual energy CT determined pulmonary blood volume will be measured in a total of 120 subjects before and after hyperoxia, hypoxia, and sildenafil.
|
80 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT02682147 |
201508782
R01HL130883 |
|
July 10, 2017 |
February 2023 |
December 2023 |
February 15, 2016 |
October 23, 2017 |
|
- University of Iowa
Iowa City, Iowa, United States
|
|
| 34 |
NCT01517854 |
Enrolling by invitation |
Revatio Portal-Pulmonary Arterial Hypertension Trial |
- Portopulmonary Hypertension
|
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University Health Network, Toronto
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in PVR after 16 weeks of treatment
- For patients with a PVR>450 dynes/sec/cm5 at baseline, number of patients who have PVR below 350 dynes/sec/cm5 after 16 weeks of study drug will be determined
- Hospitalizations
- (and 9 more...)
|
44 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01517854 |
RePo1 |
RePo1 |
October 2012 |
November 2018 |
December 30, 2019 |
January 25, 2012 |
January 12, 2018 |
|
- Lawson Health Research Institute (London Health Sciences Centre Research Inc.)
London, Ontario, Canada - University Health Network
Toronto, Ontario, Canada - Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Canada
|
|
| 35 |
NCT03012386 |
Recruiting |
CD36 in Nutrient Delivery and Its Dysfunction |
- Insulin Resistance
- Endothelial Dysfunction
|
|
Interventional
|
Phase 1
Phase 2 |
- Vanderbilt University Medical Center
- Washington University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- insulin-stimulated microvascular recruitment.
- Insulin sensitivity
|
40 |
All |
18 Years to 50 Years (Adult) |
NCT03012386 |
160955 |
|
January 2017 |
July 2020 |
December 2020 |
January 6, 2017 |
January 29, 2018 |
|
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
|
|
| 36 |
NCT03053739 |
Recruiting |
To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis |
- Associated Pulmonary Arterial Hypertension
|
- Drug: Sildenafil 20mg and Bosentan 62.5mg
- Drug: Sildenafil 20mg and Placebo
|
Interventional
|
Phase 4 |
- Postgraduate Institute of Medical Education and Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Pulmonary artery pressures
- 1.Change in 6 Minute walk distance
- Time To Clinical Worsening (TTCW)
- Emergent side effects of Sildenafil and Bosentan
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03053739 |
MK/2927/DM/9430 |
BosSilSS |
December 2016 |
December 2017 |
December 2017 |
February 15, 2017 |
February 15, 2017 |
|
- Dr Preksha Dwivedi
Chandigarh, India
|
|
| 37 |
NCT02057458 |
Active, not recruiting |
Blood Flow and Vascular Function in Cystic Fibrosis |
|
- Drug: Acute (1 hour) Sildenafil
- Drug: Sub-Chronic (4 weeks) Sildenafil
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Augusta University
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Exercise Capacity
- Flow-Mediated Dilation (FMD)
- Arterial Stiffness Evaluation (PWV)
- Physio Flow
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02057458 |
DK100783
R21DK100783 |
CF-FLOW |
April 2014 |
July 2018 |
December 2018 |
February 7, 2014 |
June 27, 2018 |
|
- Augusta University
Augusta, Georgia, United States
|
|
| 38 |
NCT02990078 |
Recruiting |
Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury |
|
- Drug: Sildenafil citrate
- Device: Functional Near Infared Spectroscopy
- Other: Hypercapnia Challenge
|
Observational
|
|
- University of Pennsylvania
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in CVR prior to sildenafil administration
- Change CVR after sildenafil administration
- Relationship of CVR with symptom reports, as measured by the Neurobehavioral Symptom Inventory (NBSI).
|
168 |
All |
18 Years and older (Adult, Older Adult) |
NCT02990078 |
825942 |
|
December 2016 |
January 2025 |
|
December 12, 2016 |
August 17, 2017 |
|
- Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
|
|
| 39 |
NCT01913847 |
Recruiting |
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension |
- Pulmonary Hypertension
- Systolic Dysfunction
|
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Hanmi Pharmaceutical Company Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in 6-min-walk test distance
- Change from baseline in systolic pulmonary arterial pressure (PAP)
- Change from baseline in [NT pro-BNP]
- (and 3 more...)
|
144 |
All |
20 Years and older (Adult, Older Adult) |
NCT01913847 |
HM-SIL-301 |
|
September 2013 |
December 2018 |
December 2018 |
August 1, 2013 |
November 27, 2017 |
|
- 11 institutions including Hallym University Dongtan Sacred Heart Hospital
Seoul, Korea, Republic of
|
|
| 40 |
NCT02975037 |
Not yet recruiting |
Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors |
|
- Drug: Sildenafil
- Drug: Erythromycin
- Drug: Itraconazole
|
Interventional
|
Phase 4 |
- Seoul National University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Quantification of endogenous metabolites (plasma)
- Quantification of endogenous metabolites (urine)
- Peak plasma concentration (Cmax)
- Area under the plasma concentration versus time curve (AUC)
|
32 |
Male |
19 Years to 50 Years (Adult) |
NCT02975037 |
CYP3A_DDI |
|
December 2016 |
April 2017 |
April 2017 |
November 29, 2016 |
November 29, 2016 |
|
|
|
| 41 |
NCT03143465 |
Recruiting |
Pharmacologically Triggered Migraine Without Aura and Neuroimaging |
|
- Drug: Calcitonin Gene-Related Peptide
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- CGRP and sildenafil induced MRI-changes
|
36 |
All |
18 Years to 50 Years (Adult) |
NCT03143465 |
H-15019063 |
|
August 2016 |
December 2018 |
December 2018 |
May 8, 2017 |
May 8, 2017 |
|
- Danish Headache Center, University Hospital
Glostrup, Denmark
|
|
| 42 |
NCT00955929 |
Active, not recruiting |
Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy |
- Penile Cancer
- Erectile Dysfunction
- Radical Prostatectomy
|
- Drug: Placebo QHS and sildenafil and questionnaires
- Drug: Sildenafil and questionnaire
- Drug: Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
|
Interventional
|
Not Applicable |
- Memorial Sloan Kettering Cancer Center
- Pfizer
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Difference in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) between the 3 groups at 24 months.
- The time to return of spontaneous functional erections.
- The time for patients to respond to oral erectogenic therapy.
- The proportion of patients who have normalization of their erectile function (normalization of the EF domain of the IIEF).
|
100 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00955929 |
09-005 |
|
August 2009 |
August 2019 |
August 2019 |
August 10, 2009 |
September 5, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
| 43 |
NCT03406169 |
Recruiting |
Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy |
- Erectile Dysfunction
- Prostate Cancer
|
- Drug: Sildenafil 25 MG Oral Tablet
- Drug: Pentoxifylline
- Other: Placebo
|
Interventional
|
Phase 3 |
- Brooke Army Medical Center
- Walter Reed National Military Medical Center
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Erectile function
- Penile length
|
180 |
Male |
30 Years to 89 Years (Adult, Older Adult) |
NCT03406169 |
C.2017.001 |
|
February 13, 2017 |
December 2021 |
March 2022 |
January 23, 2018 |
January 23, 2018 |
|
- Brooke Army Medical Center
San Antonio, Texas, United States
|
|
| 44 |
NCT03364335 |
Enrolling by invitation |
The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity |
|
- Drug: Leucine
- Drug: Sildenafil Citrate 1.0 mg
- Drug: Sildenafil Citrate 4.0 mg
- (and 2 more...)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percentage body weight change
- Change in absolute body weight
- Change in percentage of patients with ≥5% body weight loss
- (and 6 more...)
|
267 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03364335 |
NS-WM-01 |
|
January 8, 2018 |
November 2018 |
November 2018 |
December 6, 2017 |
March 22, 2018 |
|
- AMR
Mobile, Alabama, United States - Catalina Research Institute
Montclair, California, United States - Northern California Research
Sacramento, California, United States - (and 12 more...)
|
|
| 45 |
NCT03382106 |
Recruiting |
Smoking Cessation and Functional CT Assessment |
|
- Drug: Sildenafil 20 MG
- Drug: Placebo Oral Tablet
|
Interventional
|
Phase 4 |
- Eric A. Hoffman
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Iowa
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Dual energy CT determined pulmonary blood volume will be measured in a total of 80 smoking cessation subjects.
|
80 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT03382106 |
201706713
R01HL130883 |
|
March 19, 2018 |
February 2023 |
December 2023 |
December 22, 2017 |
July 2, 2018 |
|
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
|
|
| 46 |
NCT02946944 |
Recruiting |
Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism |
- Pulmonary Embolism
- Intermediate-high Risk
- Combination of Oral Anticoagulation Therapy and Sildenafil
|
- Drug: Sildenafil/apixaban
- Drug: apixaban
|
Interventional
|
Phase 1 |
- Meshalkin Research Institute of Pathology of Circulation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MSCT RV \ LV Index
- Echocardiogram RV \ LV Index
- Echocardiogram pressure in the pulmonary artery
- (and 5 more...)
|
100 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02946944 |
NRICP-45734 |
PSCAT |
October 2016 |
October 2020 |
October 2020 |
October 27, 2016 |
November 1, 2016 |
|
- Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology
Novosibirsk, Russian Federation
|
|
| 47 |
NCT03236818 |
Active, not recruiting |
Goal Oriented Strategy to Preserve Ejection Fraction Trial |
- Pulmonary Arterial Hypertension
|
- Drug: ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
|
Interventional
|
Phase 4 |
- VU University Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in right ventricular ejection fraction
- pulmonary vascular resistance
- mPAP
- (and 3 more...)
|
30 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03236818 |
NL41878.029.13 |
GOSPEL |
May 2013 |
September 2017 |
September 2017 |
August 2, 2017 |
August 2, 2017 |
|
- VU University Medical Center, dept Pulmonary diseases
Amsterdam, Netherlands
|
|
| 48 |
NCT02284737 |
Recruiting |
A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH |
- Pulmonary Arterial Hypertension
|
- Procedure: PADN
- Procedure: sham PADN
- Drug: Sildenafil
|
Interventional
|
Phase 4 |
- Nanjing First Hospital, Nanjing Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Pulmonary artery hypertension (PAH)- related events
- 6-minute walk distance
- Pulmonary arterial pressure
- (and 9 more...)
|
270 |
All |
18 Years and older (Adult, Older Adult) |
NCT02284737 |
FirstNanjingMU |
PADN-PAH |
November 28, 2014 |
July 30, 2021 |
July 30, 2021 |
November 6, 2014 |
March 21, 2018 |
|
- Nanjing First Hospital
Nanjing, Jiangsu, China
|
|
| 49 |
NCT03596047 |
Recruiting |
Radial Shockwave Therapy for Erectile Dysfunction |
|
- Device: Radial wave therapy
- Device: Placebo therapy
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Average score of the IIEF-EF scale
- IIEF-EF score after one month of follow-up
- Erection Hardness Score (EHS)
- Incidence of adverse events
|
80 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03596047 |
BMGC-4 |
|
April 19, 2018 |
February 2019 |
March 2019 |
July 23, 2018 |
July 23, 2018 |
|
- Boston Medical Group Colombia
Bogotá, Cundinamarca, Colombia
|
|
| 50 |
NCT03633565 |
Not yet recruiting
New |
Comparative Study of Strategies for Management of Duchenne Myopathy (DM) |
|
- Drug: Sildenafil (Phosphodiesterase inhibitors)
- Drug: Prednisolone (Steroids)
- Procedure: Mesenchymal stem cell transplantation
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 6 Minute Walk Distance (6MWD)
|
45 |
Male |
5 Years to 15 Years (Child) |
NCT03633565 |
smdmauch |
|
September 2018 |
September 2021 |
November 2021 |
August 16, 2018 |
August 16, 2018 |
|
|
|
| 51 |
NCT02891850 |
Recruiting |
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy |
- Pulmonary Arterial Hypertension
|
- Drug: Adempas (Riociguat, BAY63-2521)
- Drug: Sildenafil
- Drug: Tadalafil
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy (Y/N)
- Change in 6 Minute Walking Distance (6MWD) from baseline to 24 weeks
- Change in N-terminal pro-brain natriuretic peptide (NT-proBNP) from baseline to 24 weeks
- (and 2 more...)
|
218 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02891850 |
18588
2016-001067-36 |
REPLACE |
January 11, 2017 |
January 31, 2020 |
February 28, 2020 |
September 8, 2016 |
August 14, 2018 |
|
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- Sacramento, California, United States
- (and 104 more...)
|
|
| 52 |
NCT03462017 |
Recruiting |
Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus |
- Microvascular Coronary Artery Disease
|
- Drug: SAR247799
- Drug: Placebo
- Drug: Sildenafil
- Drug: Acetylcholine
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in Flow Mediated Dilation (FMD)
- Microvascular reactivity
- Number of adverse events
- (and 4 more...)
|
108 |
All |
18 Years to 64 Years (Adult) |
NCT03462017 |
PDY15286
2017-002592-26
U1111-1197-8124 |
|
March 7, 2018 |
October 17, 2018 |
October 17, 2018 |
March 12, 2018 |
July 10, 2018 |
|
- Investigational Site Number 2760002
Mainz, Germany - Investigational Site Number 2760001
Neuss, Germany
|
|
| 53 |
NCT00972569 |
Enrolling by invitation |
Low Dose Intravenous (IV) Infusion of BNP in the Presence and Absence of Acute Type V Phosphodiesterase (PDE V) in Improving Renal Function in Hospitalized Chronic Heart Failure (CHF) Patients With Renal Dysfunction |
- Heart Failure
- Renal Dysfunction
|
- Drug: BNP and PDE-V
- Drug: BNP
|
Interventional
|
Phase 1
Phase 2 |
- Mayo Clinic
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint for this aim will be a comparison of the 3 groups for the percent change in creatinine clearance, and blood urea nitrogen from baseline to 48 hours.
- The secondary endpoints for this aim will be a comparison of the 3 groups for the percent change in plasma, sodium excretion, aldosterone, and renal cGMP generation from baseline line to 48 hours
|
69 |
All |
18 Years and older (Adult, Older Adult) |
NCT00972569 |
09-003303
1R01HL08415501A2 |
Aim 3 BNP/PDEV |
October 2009 |
June 2018 |
September 2018 |
September 7, 2009 |
May 24, 2018 |
|
|
|
| 54 |
NCT03259516 |
Recruiting |
Nivolumab With Chemotherapy in Refractory MDS |
- Myelodysplastic Syndromes
|
- Drug: Nivolumab
- Drug: Azacitidine
- Drug: Fludarabine
- (and 5 more...)
|
Interventional
|
Phase 1
Phase 2 |
- St. Petersburg State Pavlov Medical University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Treatment-related adverse events as assessed by CTCAE v4.03
- Infectious complications
|
50 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03259516 |
18/17-n |
|
May 25, 2017 |
May 25, 2020 |
December 25, 2021 |
August 23, 2017 |
August 23, 2017 |
|
- First Pavlov State Medical University of St. Petersburg
Saint-Petersburg, Russian Federation
|
|
| 55 |
NCT01966302 |
Active, not recruiting |
Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH) |
- Pulmonary Arterial Hypertension
|
|
Interventional
|
Phase 2 |
- Los Angeles Biomedical Research Institute
- Lung Biotechnology PBC
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants experiencing Adverse Events
|
3 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01966302 |
Compassionate use BPS-314d-MR |
|
November 2013 |
December 2019 |
December 2019 |
October 21, 2013 |
February 2, 2018 |
|
- Los Angeles Biomedical research Institute
Torrance, California, United States
|
|
| 56 |
NCT01117142 |
Recruiting |
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers |
- Lymphoma, Mantle-cell
- CLL (Chronic Lymphocytic Leukemia)
- Monoclonal B-Cell Lymphocytosis
- (and 2 more...)
|
|
Observational
|
|
- National Heart, Lung, and Blood Institute (NHLBI)
- Northwell Health
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The primary endpoint is the estimate of the cell proliferation rate of tumor cells in individuals with MBL, CLL/SLL, and MCL
- Secondary endpoints include: Proliferation rate in tissue compared to blood, disappearance rate of labeled cells from the blood and tissue and the safety profile of heavy water in the study population/
|
105 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT01117142 |
100097
10-H-0097 |
|
June 3, 2010 |
|
|
May 5, 2010 |
August 21, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 57 |
NCT03361631 |
Not yet recruiting |
Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes |
- Erectile Dysfunction
- Stem Cells
- Diabetes Mellitus, Type 1
|
- Drug: Autologous Bone Marrow derived Mesenchymal Stem Cells
|
Interventional
|
Phase 1 |
- Central Hospital, Nancy, France
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the occurrence of clinical adverse event (tolerance) to intracavernous injection of autologous MSC in patients 18 to 50 years of age with complicated type 1 diabetes mellitus with erectile dysfunction refractory to oral treatment.
- Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of the clinical score IIEF-5 (International Index of Erectile Function-5)
- Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of the EHS score
- (and 8 more...)
|
13 |
Male |
18 Years to 50 Years (Adult) |
NCT03361631 |
PHRCI2016/MESERIC-EL OSTA/NK |
MESERIC |
June 30, 2018 |
July 30, 2018 |
December 31, 2019 |
December 5, 2017 |
December 5, 2017 |
|
|
|
| 58 |
NCT03074149 |
Recruiting |
Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF) |
- Idiopathic Pulmonary Fibrosis
|
|
Observational
|
|
|
Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- comprehensive clinical picture for IPF
- access to health care and cost of caring for IPF patients over time
- implementation of treatment guidelines, used on patients diagnosed with IPF, according to the existing diagnosis guidelines
- (and 2 more...)
|
300 |
All |
40 Years and older (Adult, Older Adult) |
NCT03074149 |
1199.252 |
INDULGEIPF |
April 4, 2017 |
April 30, 2021 |
April 30, 2021 |
March 8, 2017 |
September 5, 2018 |
|
- Gen. Hosp. of Chest Diseases "Sotiria", Univ. Resp. Med.
Athens, Greece - Sotiria Hospital Athens, 7th Pulmonary Clinic
Athens, Greece - Attikon General University Hospital
Athens, Greece - (and 4 more...)
|
|
| 59 |
NCT02565030 |
Active, not recruiting |
Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome |
- Chronic Thromboembolic Pulmonary Hypertension
- Idiopathic Pulmonary Arterial Hypertension
|
|
Observational
|
|
- Sheffield Teaching Hospitals NHS Foundation Trust
- University of Sheffield
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Death
- Mean Pulmonary Arterial Pressure(mm of Hg)
- Diffusion across the lung of Carbon Monoxide(mmol/min/KPa)
- (and 4 more...)
|
1200 |
All |
18 Years and older (Adult, Older Adult) |
NCT02565030 |
STH18804 |
|
February 2015 |
October 2021 |
October 2021 |
October 1, 2015 |
June 14, 2018 |
|
- Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, South Yorkshire, United Kingdom
|
|
| 60 |
NCT01347216 |
Recruiting |
COMPERA / COMPERA-KIDS |
- Pulmonary Arterial Hypertension (PAH)
- Pulmonary Hypertension (PH)
|
|
Observational
|
|
- Technische Universität Dresden
- GWT-TUD GmbH
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients on monotherapy vs combination therapies at baseline and during follow-up (drug utilisation patterns)
- Number of patients in the various Dana Point groups (patient characteristics in PAH and non-PAH pulmonary hypertension groups)
- Probability of survival in the various Dana Point groups (PAH and non-PAH pulmonary hypertension groups) by Kaplan-Meier estimate
|
9000 |
All |
Child, Adult, Older Adult |
NCT01347216 |
COMPERA |
COMPERA |
June 2007 |
December 2019 |
December 2019 |
May 4, 2011 |
July 26, 2018 |
|
- Dept. of Pneumology, University
Leuven, Belgium - DRK-Klinikum Köpenick
Berlin, Germany - Lung Centre, University of Giessen
Giessen, Germany - (and 5 more...)
|
|
| 61 |
NCT03610217 |
Not yet recruiting |
Pragmatic Clinical Trials in Scleroderma |
- Scleroderma, Systemic
- Sclerosis, Systemic
|
- Other: Interstitial lung disease induction algorithm
- Other: Pulmonary arterial hypertension algorithm
- Other: Raynaud's phenomenon algorithm
- (and 7 more...)
|
Interventional
|
Not Applicable |
- University of West London
- University of Western Ontario, Canada
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Forced vital capacity %
- Bleeding
- Raynaud's phenomenon visual analog scale
- (and 8 more...)
|
400 |
All |
18 Years and older (Adult, Older Adult) |
NCT03610217 |
111419 |
PCTS |
October 2018 |
October 2021 |
October 2021 |
August 1, 2018 |
August 6, 2018 |
|
- Saint Joseph's Health Care London
London, Ontario, Canada
|
|
Create an RSS feed from your search for:
Download the search results for: